Article Details
Retrieved on: 2024-09-28 10:14:48
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article discusses Sahajanand Medical Technologies' (SMT) recent approval from Australia's Therapeutic Goods Administration (TGA) for their drug-eluting stent, Supraflex Cruz, emphasizing MedTech advances in interventional cardiology and cardiovascular care in Australia.
Article found on: www.biospectrumasia.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here